NDC product
Raloxifene hydrochloride
NDC 71209-082 · Cadila Pharmaceuticals Limited
Key facts
| Product NDC | 71209-082 |
|---|---|
| Proprietary name | Raloxifene hydrochloride |
| Nonproprietary name | Raloxifene hydrochloride |
| Substances | RALOXIFENE HYDROCHLORIDE |
| Dosage form | TABLET, COATED |
| Route | ORAL |
| Labeler | Cadila Pharmaceuticals Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211324 |
| Pharmacologic classes | Estrogen Agonist/Antagonist [EPC], Selective Estrogen Receptor Modulators [MoA] |
| Marketing start | Dec 30, 2017 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: